Regeneron Pharmaceuticals (REGN) Interest & Investment Income (2009 - 2017)
Regeneron Pharmaceuticals' quarterly Interest & Investment Income came in at -$6.0 million in Q4 2017, down 114.92% year-on-year from $40.4 million in Q4 2016, and up 2.38% quarter-over-quarter from -$6.2 million in Q3 2017.
Regeneron Pharmaceuticals has reported Interest & Investment Income for 9 years, with the latest figure at -$6.0 million in Q4 2017.
- For the quarter ending Q4 2017, Interest & Investment Income fell 114.92% year-over-year to -$6.0 million; the trailing twelve-month figure through Dec 2017 stood at -$25.1 million (down 249.12% YoY), and the FY2017 full-year result was -$25.1 million, down 249.12% from the prior year.
- Interest & Investment Income for Q4 2017 stood at -$6.0 million, up from -$6.2 million in the prior quarter.
- The five-year high for Interest & Investment Income was $2.1 million in Q3 2015, with the low at -$18.2 million in Q4 2015.
- Average Interest & Investment Income over 5 years is -$2.5 million, with a median of -$873500.0 recorded in 2016.
- Year-over-year, Interest & Investment Income jumped 105.48% in 2014 and tumbled 1566.67% in 2016.
- Tracing REGN's Interest & Investment Income over 5 years: stood at -$2.3 million in 2013, then jumped by 174.24% to $1.7 million in 2014, then slumped by 1186.11% to -$18.2 million in 2015, then surged by 84.58% to -$2.8 million in 2016, then tumbled by 114.92% to -$6.0 million in 2017.
- The last three Interest & Investment Income figures came in at -$6.0 million (Q4 2017), -$6.2 million (Q3 2017), and -$5.4 million (Q2 2017), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 19.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | -6.04 Mn |
| Sep 30, 2017 | -6.18 Mn |
| Jun 30, 2017 | -5.40 Mn |
| Mar 31, 2017 | -7.50 Mn |
| Dec 31, 2016 | -2.81 Mn |
| Sep 30, 2016 | -496,000.00 |
| Jun 30, 2016 | -1.25 Mn |
| Mar 31, 2016 | -2.64 Mn |
| Dec 31, 2015 | -18.21 Mn |
| Sep 30, 2015 | 2.14 Mn |
| Jun 30, 2015 | 1.65 Mn |
| Mar 31, 2015 | 180,000.00 |
| Jun 30, 2014 | 1.68 Mn |
| Mar 31, 2014 | 937,000.00 |
| Dec 31, 2013 | -2.26 Mn |
| Sep 30, 2013 | 618,000.00 |
| Jun 30, 2013 | 954,000.00 |
| Mar 31, 2013 | 456,000.00 |
| Dec 31, 2012 | 384,000.00 |
| Sep 30, 2012 | 517,000.00 |
| Jun 30, 2012 | 501,000.00 |
| Mar 31, 2012 | 610,000.00 |
| Dec 31, 2011 | 799,000.00 |
| Sep 30, 2011 | 715,000.00 |
| Jun 30, 2011 | 998,000.00 |
| Mar 31, 2011 | 1.04 Mn |
| Dec 31, 2010 | 638,000.00 |
| Sep 30, 2010 | 453,000.00 |
| Jun 30, 2010 | 592,000.00 |
| Mar 31, 2010 | 439,000.00 |
| Dec 31, 2009 | 553,000.00 |
| Sep 30, 2009 | 857,000.00 |
| Jun 30, 2009 | 1.33 Mn |